Table 3.
Associations of sex and risk of mortality among gastric cancer patients with signet-ring cells by subgroups
| Variable |
Male
|
Menstrual female
|
Menopausal female
|
P -interaction3 | |||
|
n
1
(%)
|
HR (95%CI)2
|
n
1
(%)
|
HR (95%CI)2
|
n
1
(%)
|
HR (95%CI)2
|
||
| BMI (kg/m2) | 0.014 | ||||||
| > 24 | 501 (53.6) | Ref | 41 (22.7) | 0.56 (0.27–1.16) | 117 (37.1) | 1.04 (0.72–1.50) | |
| ≤ 24 | 434 (46.4) | Ref | 140 (77.4) | 0.58 (0.39–0.85) | 198 (62.9) | 0.84 (0.62–1.12) | |
| Signet-ring cell proportion (%) | 0.038 | ||||||
| ≤ 50 | 733 (78.4) | Ref | 129 (71.3) | 0.56 (0.38–0.82) | 247 (78.4) | 0.94 (0.74–1.21) | |
| > 50 | 202 (21.6) | Ref | 52 (28.7) | 0.73 (0.33–1.61) | 68 (21.6) | 0.74 (0.40–1.35) | |
| Adjuvant chemotherapy | < 0.001 | ||||||
| No | 598 (64.0) | Ref | 119 (65.8) | 0.38 (0.22–0.65) | 207 (65.7) | 1.01 (0.75–1.36) | |
| Yes | 337 (36.0) | Ref | 62 (34.3) | 0.83 (0.53–1.29) | 108 (34.3) | 0.80 (0.56–1.16) | |
| Neoadjuvant chemotherapy | < 0.001 | ||||||
| No | 861 (92.1) | Ref | 165 (91.2) | 0.53 (0.36–0.77) | 289 (91.8) | 0.80 (0.35–1.82) | |
| Yes | 74 (7.9) | Ref | 16 (8.8) | 0.97 (0.76–1.25) | 26 (8.3) | 0.65 (0.33–1.26) | |
| Nerve invasion | 0.0294 | ||||||
| No | 184 (19.7) | Ref | 54 (29.8) | 0.36 (0.07–1.86) | 75 (23.8) | 0.78 (0.27–2.27) | |
| Yes | 477 (51.0) | Ref | 87 (48.1) | 0.60 (0.40–0.89) | 150 (47.6) | 0.91 (0.69–1.21) | |
| Unknown | 274 (29.3) | Ref | 40 (22.1) | 0.65 (0.31–1.39) | 90 (28.6) | 0.95 (0.60–1.49) | |
| Lymphovascular invasion | < 0.004 | ||||||
| No | 249 (26.6) | Ref | 70 (38.7) | 0.89 (0.40–1.95) | 97 (30.8) | 1.13 (0.61–2.11) | |
| Yes | 373 (39.9) | Ref | 56 (30.9) | 0.49 (0.30–0.80) | 125 (39.7.2) | 0.81 (0.59–1.10) | |
| Unknown | 313 (33.5) | Ref | 55 (30.4) | 0.68 (0.37–1.23) | 93 (29.5) | 1.23 (0.80–1.91) | |
Column percentage was reported for the overall sample; percentage can differ slightly from 100% because of rounding.
The Cox proportional hazards model included gender, BMI, signet-ring cell proportion, T stage, N stage, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphovascular invasion.
Wald test was used to examine the interaction term between sex (male, menstrual female, and menopausal female) and BMI, signet-ring cell proportion, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphovascular invasion.
The P value shows the outcome of interaction test between sex difference and nerve invasion (no vs yes) and lymphovascular invasion (no vs yes).
BMI: Body mass index. P < 0.05 indicates statistical significance.